Veracyte (VCYT) Launches Envisia Genomic Classifier for IPF Patients
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Veracyte Announces Launch of Envisia™ Genomic Classifier for Improved Diagnosis of Idiopathic Pulmonary Fibrosis at CHEST Annual Meeting 2016
October 25, 2016 8:01 AM EDTSOUTH SAN FRANCISCO, Calif., Oct. 25, 2016 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company that reduces unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced the launch of the Envisia Genomic Classifier at the CHEST Annual Meeting 2016 in Los Angeles. Envisia is expected to be the first commercially available test to help patients with suspected idiopathic pulmonary fibrosis (IPF) secure accurate diagnoses more quickly than the currently available process and without the need for invasive... More